ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Comparison of Clinical Outcomes of Belatacept- and Tacrolimus-Based Immunosuppression in Renal Transplant Recipients.

X. Wen,1 M. Casey,1 A. Santos,1 A. Hartzema,2 K. Womer.1

1Department of Medicine, University of Florida, Gainesville, FL
2Department of Pharmaceutical Outcomes and Policy, University of Florida, Gainesville, FL.

Meeting: 2016 American Transplant Congress

Abstract number: 289

Keywords: Immunosuppression, Kidney transplantation, Rejection, Renal function

Session Information

Date: Monday, June 13, 2016

Session Name: Concurrent Session: Belatacept and Steroid Withdrawal in Kidney Transplantation

Session Time: 4:30pm-6:00pm

 Presentation Time: 5:42pm-5:54pm

Location: Ballroom A

Related Abstracts
  • Comparison of Pharmacokinetic and Clinical Outcomes of Tacrolimus Hexal® with Prograf® Based Regimen in De Novo Kidney Transplant Recipients: Results from the Randomized, SparTacus Study.
  • Belatacept Based Immunosuppression and Incidence of Proteinuria in Kidney Transplant Recipients

To examine the utilization and clinical outcomes of belatacept in the real clinical setting, a retrospective cohort study was conducted using SRTR data that compared 1-year clinical outcomes between belatacept- and tacrolimus-treated adult kidney transplant recipients (KTR) from June 1, 2011 to December 01, 2014. Primary outcome, defined as incidence of biopsy-proven acute rejection (BPAR), and secondary outcomes, including mean estimated glomerular filtration rate (eGFR) and incidence of new-onset diabetes after transplantation (NODAT), were analyzed in a multivariate Cox model. Subgroup analyses included patients with or without lymphocyte-depleting (LD) induction and those meeting inclusion criteria for the BENEFIT and BENEFIT-EXT trials. Of 50 244 total patients, 417 received belatacept+tacrolimus, 458 received belatacept alone, and 49 369 received tacrolimus alone at hospital discharge. Significantly increased risk of BPAR associated with belatacept alone was identified in the overall study cohort compared to tacrolimus alone, with highest rates in those without LD induction (aHR: 2.65; 95%CI: 1.90-3.70, P<.0001). No significant difference in BPAR was demonstrated between belatacept+tacrolimus and tacrolimus alone. In the subgroup meeting criteria for the BENEFIT-EXT trial, kidney function was superior in KTR given belatacept+tacrolimus and belatacept alone versus tacrolimus alone (eGFR: 65.6 vs. 60.4. vs. 54.3 ml/min/1.73M2, respectively, P<.001). The risk of NODAT was significantly lower with belatacept+tacrolimus and belatacept alone versus tacrolimus alone (1.7% vs 2.2% vs 3.8%, respectively, P=.01). Despite improved graft function with belatacept, it may be advisable to add short-term tacrolimus during the first year post-transplant and/or consider LD induction in higher risk patients, as the risk to benefit ratio allows.

Groups

Adjusted Hazard Ratio (95% CI, P value) for 1-Year Biopsy Proven Acute Rejection, Belatacept Alone vs Tacrolimus Alone

All Recipients

2.36 (1.82 – 3.05, P<.001)

Recipients Used Lymphocyte- Depleting Induction Drugs

1.86 (1.20 – 2.90, P=.006)

Recipients Used Non Lymphocyte- Depleting Induction Drugs

2.65 (1.90 – 3.70, P<.001)

BENEFIT Recipients

2.51 (1.79 – 3.52, P<.001)

BENEFIT-EXT Recipients

1.74 (1.06 – 2.85, P=.027)

CITATION INFORMATION: Wen X, Casey M, Santos A, Hartzema A, Womer K. Comparison of Clinical Outcomes of Belatacept- and Tacrolimus-Based Immunosuppression in Renal Transplant Recipients. Am J Transplant. 2016;16 (suppl 3).

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Wen X, Casey M, Santos A, Hartzema A, Womer K. Comparison of Clinical Outcomes of Belatacept- and Tacrolimus-Based Immunosuppression in Renal Transplant Recipients. [abstract]. Am J Transplant. 2016; 16 (suppl 3). https://atcmeetingabstracts.com/abstract/comparison-of-clinical-outcomes-of-belatacept-and-tacrolimus-based-immunosuppression-in-renal-transplant-recipients/. Accessed April 20, 2021.

« Back to 2016 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Penis Transplantation: First U.S. Experience.
  • Live Related Kidney Transplant Experience in Abuja, Nigeria – First Eight Cases Ever.
    • Assessment of Anti-A and Anti-B Antibody Titers in Different IVIG Preparations: Correlation with Risk for Hemolysis

    Visit Our Partner Sites

    American Transplant Congress (ATC)

    Visit the official site for the American Transplant Congress »

    American Journal of Transplantation

    The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

    American Society of Transplantation (AST)

    An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

    American Society of Transplant Surgeons (ASTS)

    The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

    Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

    Privacy Policy | Terms of Use

    loading Cancel
    Post was not sent - check your email addresses!
    Email check failed, please try again
    Sorry, your blog cannot share posts by email.
    This site uses cookies: Find out more.